4 found
Order:
  1.  92
    Public Stem Cell Banks: Considerations of Justice in Stem Cell Research and Therapy.Ruth R. Faden, Liza Dawson, Alison S. Bateman-House, Dawn Mueller Agnew, Hilary Bok, Dan W. Brock, Aravinda Chakravarti, Xiao-Jiang Gao, Mark Greene, John A. Hansen, Patricia A. King, Stephen J. O'Brien, David H. Sachs, Kathryn E. Schill, Andrew Siegel, Davor Solter, Sonia M. Suter, Catherine M. Verfaillie, LeRoy B. Walters & John D. Gearhart - 2003 - Hastings Center Report 33 (6):13-27.
    If stem cell-based therapies are developed, we will likely confront a difficult problem of justice: for biological reasons alone, the new therapies might benefit only a limited range of patients. In fact, they might benefit primarily white Americans, thereby exacerbating long-standing differences in health and health care.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   11 citations  
  2.  48
    Safety Issues In Cell-Based Intervention Trials.Liza Dawson, Alison S. Bateman-House, Dawn Mueller Agnew, Hilary Bok, Dan W. Brock, Aravinda Chakravarti, Mark Greene, Patricia King, Stephen J. O'Brien, David H. Sachs, Kathryn E. Schill, Andrew Siegel & Davor Solter - 2003 - Fertility and Sterility 80 (5):1077-1085.
    We report on the deliberations of an interdisciplinary group of experts in science, law, and philosophy who convened to discuss novel ethical and policy challenges in stem cell research. In this report we discuss the ethical and policy implications of safety concerns in the transition from basic laboratory research to clinical applications of cell-based therapies derived from stem cells. Although many features of this transition from lab to clinic are common to other therapies, three aspects of stem cell biology pose (...)
    Direct download  
     
    Export citation  
     
    Bookmark   4 citations  
  3. Public Stem Cell Banks.Hilary Bok Mueller Agnew, Danw Brock, Aravinda Chakravarti, Xiao-Jiang Gao, Mark Greene, John A. Hansen, Patricia A. King, Stephen J. O'brien, David H. Sachs & Kathryn E. Schill - 2003 - Hastings Center Report 33 (6):13-27.
     
    Export citation  
     
    Bookmark  
  4.  13
    Revealing rate‐limiting steps in complex disease biology: The crucial importance of studying rare, extreme‐phenotype families.Aravinda Chakravarti & Tychele N. Turner - 2016 - Bioessays 38 (6):578-586.
    The major challenge in complex disease genetics is to understand the fundamental features of this complexity and why functional alterations at multiple independent genes conspire to lead to an abnormal phenotype. We hypothesize that the various genes involved are all functionally united through gene regulatory networks (GRN), and that mutant phenotypes arise from the consequent perturbation of one or more rate‐limiting steps that affect the function of the entire GRN. Understanding a complex phenotype thus entails unraveling the details of each (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark